Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.76 |
| ▸ | EGFR | P00533 | 3/20 | 0.67 |
| ▸ | KDR | P35968 | 2/20 | 0.67 |
| ▸ | RET | P07949 | 1/20 | 0.67 |
| ▸ | KIF5B | P33176 | 1/20 | 0.67 |
| ▸ | LCK | P06239 | 1/20 | 0.67 |
| ▸ | FLT3 | P36888 | 2/20 | 0.53 |
| ▸ | BRAF | P15056 | 8/20 | 0.52 |
| ▸ | RAF1 | P04049 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18158551 | 0.85 | KDM1A (0.62) | KDM1AEGFRKDRRETKIF5B | |
| SCHEMBL8813070 | 0.81 | KDM1A (0.66) | KDM1AEGFRKDRRETKIF5B | |
| SCHEMBL1012180 | 0.81 | KDR (0.73) | KDM1AEGFRKDRRETKIF5B | |
| SCHEMBL7209616 | 0.81 | KDR (1.00) | KDM1AEGFRKDRRETKIF5B | |
| SCHEMBL4386131 | 0.81 | EGFR (0.59) | KDM1AEGFRKDRRETKIF5B | |
| SCHEMBL2473728 | 0.79 | KIT (0.61) | KDM1AEGFRKDRRETKIF5B | |
| SCHEMBL19916680 | 0.79 | EGFR (0.70) | EGFRKDRRETKIF5BLCK | |
| SCHEMBL6181186 | 0.78 | RET (0.56) | KDM1AEGFRKDRRETKIF5B | |
| SCHEMBL17278106 | 0.78 | KDR (0.72) | EGFRKDRRETKIF5BLCK | |
| SCHEMBL14478889 | 0.77 | EGFR (0.58) | KDM1AEGFRKDRRETKIF5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | claimed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | claimed |
| CN-1167422-C | Quinazoline derivatives as angiogenesis inhibitors | — | 2004-09-22 | — | — | CN | claimed |
| CN-1346271-A | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA UK LTD (SE) | 2002-04-24 | — | — | CN | claimed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | claimed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | claimed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| CN-100360505-C | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2008-01-09 | — | — | CN | disclosed |
| US-7074800-B1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| US-5721237-A | ADMINISTERING FOR THE SELECTIVE TREATMENT OF CELL GROWTH AND DIFFERENTIATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-02-24 | — | — | US | disclosed |
| US-5714493-A | ANTIINFLAMMATORY AGENT | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| US-5710158-A | INHIBITORS OF PROTEIN TYROSINE KINASE AND EPIDERMAL GROWTH FACTOR | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-01-20 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1996039145-A1 | PROTEIN TYROSINE KINASE ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS HAVING SELECTIVE INHIBITION OF HER-2 AUTOPHOSPHORYLATION PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| WO-1995015758-A1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | KDM1A 2417/4885EGFR 500/4885KDR 3/4885 |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | KDM1A 2501/4885EGFR 549/4885KDR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.